microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.

Bioengineered · 2022 · PMC8805988 · PMID 34968160

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a decreasing trendP < 0.05actually significant

IHC data displayed a decreasing trend in PD-L1 expression in the control group, the 1 Gy group, the 1 Gy+1 μM group, and the 1 Gy+1 μM+miR-20b-5p group ( P < 0.05, Figure 6(d) ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.